MFW
SRPT icon

Mosaic Family Wealth’s Sarepta Therapeutics SRPT Stock Holding History

Mosaic Family Wealth’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,000
Closed -$19K – 821
2016
Q1 		$19K Buy
+1,000
New +$17.5K 0.01% 443

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Mosaic Family Wealth's SRPT Position: Q4 2021 in Review

Mosaic Family Wealth held its Sarepta Therapeutics (SRPT) position steady in Q4 2021 at 3,269 shares worth $294K. The position accounts for 0.08% of the portfolio, ranked #138.

Mosaic Family Wealth first reported a position in SRPT in Q4 2015 and has held it in 25 quarters since. The position peaked at $699K in Q4 2020. 344 funds tracked by Wall St. Rank hold SRPT as of Q4 2021.

  • Mosaic Family Wealth held 3,269 shares of Sarepta Therapeutics worth $294K as of Q4 2021.
  • Mosaic Family Wealth left its Sarepta Therapeutics share count unchanged in Q4 2021.
  • Sarepta Therapeutics made up 0.08% of Mosaic Family Wealth's portfolio in Q4 2021, its #138 holding.
  • Mosaic Family Wealth first reported a position in Sarepta Therapeutics in Q4 2015 and has held it in 25 quarters since.
  • Mosaic Family Wealth's Sarepta Therapeutics position peaked at $699K in Q4 2020.
  • 344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2021.

Based on Mosaic Family Wealth's 13F filing for Q4 2021, filed 25 Jan 2022.